Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Greko II study of orteronel in advanced granulosa cell ovarian tumors
2013-003128-35Phase 2Terminated
- Sponsor
- Grupo Español de Tumores Huérfanos e Infrecuentes
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orteronel in granulosa cell tumor (GCT) and ovarian granulosa cell tumor (OGCT), sponsored by Grupo Español de Tumores Huérfanos e Infrecuentes. Primary endpoint: Clinical benefit rate. Started Mar 2014; status: terminated.
02
Drugs
orteronel
03
Conditions
granulosa cell tumor (GCT)ovarian granulosa cell tumor (OGCT)
Beyond the preview
Go deeper on 2013-003128-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003128-35.